Goldman Sachs’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-48,200
| Closed | -$3.81M | – | 6737 |
|
|
2025
Q4 | $3.81M | Sell |
48,200
-113,000
| -70% | -$8.51M | ﹤0.01% | 3992 |
|
|
2025
Q3 | $10.5M | Buy |
+161,200
| New | +$7.87M | ﹤0.01% | 2905 |
|
|
2025
Q1 | – | Sell |
-50,000
| Closed | -$1.75M | – | 6236 |
|
|
2024
Q4 | $1.75M | Hold |
50,000
| – | – | ﹤0.01% | 4398 |
|
|
2024
Q3 | $2M | Buy |
+50,000
| New | +$2.33M | ﹤0.01% | 4154 |
|
|
2024
Q2 | – | Sell |
-12,000
| Closed | -$520K | – | 5786 |
|
|
2024
Q1 | $520K | Sell |
12,000
-18,000
| -60% | -$858K | ﹤0.01% | 4730 |
|
|
2023
Q4 | $1.52M | Buy |
+30,000
| New | +$1.44M | ﹤0.01% | 4131 |
|
|
2020
Q2 | – | Sell |
-20,000
| Closed | -$946K | – | 5342 |
|
|
2020
Q1 | $946K | Buy |
+20,000
| New | +$1.11M | ﹤0.01% | 3805 |
|
|
2019
Q3 | – | Sell |
-250,000
| Closed | -$16.1M | – | 5269 |
|
|
2019
Q2 | $16.1M | Buy |
+250,000
| New | +$17.7M | ﹤0.01% | 2020 |
|
|
2019
Q1 | – | Sell |
-23,900
| Closed | -$1.29M | – | 5288 |
|
|
2018
Q4 | $1.29M | Hold |
23,900
| – | – | ﹤0.01% | 3824 |
|
|
2018
Q3 | $1.23M | Hold |
23,900
| – | – | ﹤0.01% | 3917 |
|
|
2018
Q2 | $996K | Hold |
23,900
| – | – | ﹤0.01% | 4079 |
|
|
2018
Q1 | $1.05M | Sell |
23,900
-29,100
| -55% | -$1.48M | ﹤0.01% | 4016 |
|
|
2017
Q4 | $2.67M | Sell |
53,000
-8,600
| -14% | -$472K | ﹤0.01% | 3554 |
|
|
2017
Q3 | $3.12M | Buy |
61,600
+23,900
| +63% | +$1.25M | ﹤0.01% | 3588 |
|
|
2017
Q2 | $1.92M | Buy |
+37,700
| New | +$1.76M | ﹤0.01% | 3876 |
|
|
2016
Q4 | – | Sell |
-90,000
| Closed | -$3.3M | – | 6980 |
|
|
2016
Q3 | $3.3M | Sell |
90,000
-62,400
| -41% | -$1.95M | ﹤0.01% | 3397 |
|
|
2016
Q2 | $3.55M | Buy |
152,400
+87,400
| +134% | +$2.82M | ﹤0.01% | 3145 |
|
|
2016
Q1 | $2.63M | Sell |
65,000
-110,200
| -63% | -$4.48M | ﹤0.01% | 3234 |
|
|
2015
Q4 | $10.8M | Buy |
175,200
+75,700
| +76% | +$4.08M | ﹤0.01% | 2195 |
|
|
2015
Q3 | $4.02M | Sell |
99,500
-104,700
| -51% | -$5.42M | ﹤0.01% | 3077 |
|
|
2015
Q2 | $11.8M | Buy |
204,200
+99,500
| +95% | +$6.33M | ﹤0.01% | 2202 |
|
|
2015
Q1 | $6.67M | Sell |
104,700
-165,300
| -61% | -$11.2M | ﹤0.01% | 2630 |
|
|
2014
Q4 | $16.7M | Sell |
270,000
-100,000
| -27% | -$4.93M | 0.01% | 1949 |
|
|
2014
Q3 | $14.4M | Sell |
370,000
-154,800
| -29% | -$5.49M | ﹤0.01% | 2059 |
|
|
2014
Q2 | $18.1M | Buy |
524,800
+1,400
| +0.3% | +$44.1K | 0.01% | 1874 |
|
|
2014
Q1 | $22.6M | Buy |
523,400
+467,600
| +838% | +$22.7M | 0.01% | 1671 |
|
|
2013
Q4 | $2.22M | Hold |
55,800
| – | – | ﹤0.01% | 3963 |
|
|
2013
Q3 | $2.1M | Buy |
+55,800
| New | +$1.67M | ﹤0.01% | 3875 |
|
Other funds holding IONS
VPM
VCM
Goldman Sachs's IONS Position: Q1 2026 in Review
Goldman Sachs increased its Ionis Pharmaceuticals (IONS) stake by 99% in Q1 2026, buying an estimated $66.6M and bringing the position to 1,699,847 shares worth $128M. The position accounts for 0.01% of the portfolio, ranked #893.
Goldman Sachs first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Goldman Sachs held 1,699,847 shares of Ionis Pharmaceuticals worth $128M as of Q1 2026.
- Goldman Sachs bought 843,881 Ionis Pharmaceuticals shares in Q1 2026, an estimated $66.6M.
- Ionis Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #893 holding.
- Goldman Sachs first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.